All In Biotech

Drug Trial Radar · NCT07116473

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2037

Study completion Dec 2037

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Conditions

  • Amyloidosis in Transthyretin (TTR)
  • Amyloidosis, Familial
  • Amyloid Cardiomyopathy
  • Amyloid Cardiomyopathy, Transthyretin-Related
  • Amyloidogenic Transthyretin (ATTR) Amyloidosis
  • Heart Disease
  • Cardiomyopathies
  • Amyloidosis, Hereditary, Transthyretin-Related
  • Polyneuropathies
  • Amyloidosis

Interventions

  • Acoramidis (AG10)Drug

    TTR stabilizer administered orally twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the long-term safety and tolerability of acoramidis in participants with newly diagnosed ATTR-CMTime frame: The duration of study participation for the participants will be up to 5 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.